Concentra Group Holdings Parent, Inc. (CON) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted strong financial performance, including increased adjusted net income and significant revenue growth from acquisitions. The company raised its revenue and EBITDA guidance, a positive indicator. Despite some vague responses in the Q&A, the overall sentiment was positive with strong market strategy and shareholder return plans. The focus on technological investments and M&A strategy suggests growth potential. The raised guidance and strong financial metrics outweigh any concerns, suggesting a positive stock price reaction over the next two weeks.
Key Financial Performance
Total Company Revenue (Q4 2025) $539.1 million, a 15.9% growth year-over-year. Excluding contributions from Nova and Pivot acquisitions, revenue was $493.8 million, a 6.2% increase over the prior year. Growth attributed to solid growth in visits and rate, prudent cost management, and double-digit organic growth in the Onsite business operating segment.
Total Company Revenue (Full Year 2025) $2.2 billion, a 13.9% growth year-over-year despite one less revenue day. Excluding contributions from Nova and Pivot, revenue was $2 billion, a 6.4% increase over the prior year or 6.8% on a per-day basis.
Total Patient Visits (Q4 2025) Increased 9% to more than 51,000 visits per day. Workers' compensation visits per day increased 9.1%, and employer service visit volume increased 9.4%. Excluding Nova acquisition, total visits per day increased 2.6%.
Total Patient Visits (Full Year 2025) Increased 7.7% year-over-year to over 53,000 visits per day. Workers' compensation visits increased 7.7%, and employer services visits increased 8.1%. Excluding Nova acquisition, total visits per day increased 2.2%.
Revenue Per Visit (Q4 2025) Grew 3.1% year-over-year. Workers' compensation revenue per visit increased 4.1%, and employer services revenue per visit increased 1.2%. Growth driven by a shift in mix between lower dollar drug screens and higher dollar physicals.
Revenue Per Visit (Full Year 2025) Increased 4.3% year-over-year. Workers' compensation revenue per visit increased 5.3%, and employer services revenue per visit increased 2.7%.
Adjusted EBITDA (Q4 2025) $95.3 million, a 22.9% increase year-over-year. Adjusted EBITDA margin increased from 16.7% in Q4 2024 to 17.7% in Q4 2025. Growth attributed to operational efficiencies and cost management.
Adjusted EBITDA (Full Year 2025) $431.9 million, a 14.6% growth year-over-year despite one less revenue day. Adjusted EBITDA margin increased to 20% from 19.8% in 2024. Growth driven by organic performance and contributions from Nova and Pivot acquisitions.
Adjusted Net Income (Q4 2025) $36.1 million, compared to $22.2 million in Q4 2024. Adjusted earnings per share were $0.28, compared to $0.17 in Q4 2024.
Adjusted Net Income (Full Year 2025) $176 million, compared to $168.5 million in 2024. Adjusted earnings per share were $1.37, compared to $1.48 in 2024.
Onsite Health Clinic Revenue (Q4 2025) $36.2 million, a 112% increase year-over-year. Excluding Pivot acquisition, revenue grew 14.6% year-over-year.
Onsite Health Clinic Revenue (Full Year 2025) $110.2 million, a 72% increase year-over-year. Excluding Pivot acquisition, revenue grew 11.6% year-over-year.
Cost of Services (Q4 2025) $398.4 million or 73.9% of revenue, an improvement from 74.2% in Q4 2024. Improvement attributed to staffing efficiencies and operational management.
Cost of Services (Full Year 2025) 71.7% of revenue, a decrease from 72.2% in 2024. Improvement attributed to operational efficiencies despite integration costs from Nova transaction.
Operating Cash Flow (Q4 2025) $118.7 million, compared to $93.7 million in Q4 2024. Increase driven by higher earnings.
Operating Cash Flow (Full Year 2025) $279.4 million, a slight improvement over $274.7 million in 2024 despite higher cash interest expenses.
Free Cash Flow (Q4 2025) $98.6 million, compared to $77 million in Q4 2024. Increase attributed to higher operating cash flow.
Free Cash Flow (Full Year 2025) $197.8 million, with a free cash flow conversion rate of 114%, consistent with the past 5 years.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Validation studies on workers' compensation claims: Completed additional validation studies on workers' compensation claims treated by Concentra, analyzing over 550,000 claims from 2020 to 2025. Found that Concentra-treated claims cost 25% less and had 65 fewer days in claim duration compared to non-Concentra providers.
De novo site openings: Opened 2 new sites in Southern California and Miami in Q4 2025, totaling 7 new sites in 2025. Plans for 7-9 new sites in 2026, including expansion into Idaho.
M&A activity: Acquired 3 centers in California in January 2026 and plans to continue smaller bolt-on acquisitions.
Revenue growth: Q4 2025 revenue grew 15.9% year-over-year to $539.1 million. Full-year 2025 revenue reached $2.2 billion, a 13.9% increase from 2024.
Visit growth: Total patient visits increased 9% in Q4 2025 and 7.7% for the full year 2025. Workers' compensation visits grew 9.1% in Q4 2025.
Adjusted EBITDA: Q4 2025 adjusted EBITDA increased 22.9% year-over-year to $95.3 million. Full-year 2025 adjusted EBITDA grew 14.6% to $431.9 million.
Separation from Select Medical: Hired over 80% of expected FTEs for separation, with plans to complete by summer 2026, ahead of the November 2026 deadline.
New York workers' compensation fee schedule: Monitoring potential revisions to New York's workers' compensation fee schedule, which could lead to significant expansion opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Government Shutdown Impact: Limited exposure to the federal government from an employer customer standpoint, but potential risks if exposure increases in the future.
Labor Market Growth: Relatively anemic growth in the broader U.S. labor market (0.1% in 2025) could impact demand for services, though mitigated by growth in the blue-collar economy.
Separation from Select Medical: Ongoing separation activities and associated costs, including hiring and integration, could pose operational and financial challenges until fully completed by November 2026.
Workers' Compensation Fee Schedule in New York: Proposed fee schedule increases are insufficient to justify entering the New York market, limiting potential expansion opportunities.
M&A Integration Costs: Integration of Nova and Pivot acquisitions incurred significant costs, though largely completed, with potential for residual impacts.
Economic Uncertainty: Broader economic conditions and debates around labor market health could indirectly affect business performance.
Seasonal Cash Flow Variability: Seasonally low free cash flow in Q1 due to lower visits and elevated working capital requirements.
Regulatory Changes: Potential regulatory changes in workers' compensation fee schedules and other areas could impact revenue and operational strategies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Target for 2026: The company has set its revenue target at a range of $2.25 billion to $2.35 billion for the full year 2026.
Adjusted EBITDA Target for 2026: The adjusted EBITDA target is set at a range of $450 million to $470 million for 2026.
Capital Expenditures (CapEx) Target for 2026: The CapEx target is set at a range of $70 million to $80 million, which is a decrease from 2025 due to the roll-off of approximately $15 million in one-time Nova integration CapEx.
Free Cash Flow Target for 2026: The free cash flow target is set at a range of $200 million to $225 million.
Leverage Target for 2026: The company aims to achieve a leverage target of approximately 3x by the end of 2026.
Rate Growth Assumptions for 2026: The company assumes approximately 3% rate growth within the occupational health centers operating segment, with a high degree of confidence due to finalized fee schedules in major states.
Visit Growth Assumptions for 2026: The company assumes low single-digit visit growth, excluding Nova, and includes the January 3-center acquisition and 6 de novo sites with executed leases as of the guidance date.
Adjusted EBITDA Margin for 2026: The adjusted EBITDA margin is expected to remain relatively constant with 2025 at around 20%, with potential for additional margin expansion after the separation is fully complete.
De Novo Openings for 2026: The company is targeting 7 to 9 de novo openings in 2026, which would be a record for the company.
M&A Strategy for 2026: The company plans to continue with smaller bolt-on acquisition opportunities, targeting 1 to 5 center deals.
Dividend Continuation: The company announced a continuation of its dividend, with a cash dividend of $0.0625 per share declared for Q1 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payment: Concentra's Board of Directors declared a cash dividend of $0.0625 per share on February 25, 2026. The dividend will be payable on or about March 19, 2026, to stockholders of record as of the close of business on March 12, 2026.
2025 Dividend Payments: Concentra made dividend payments totaling $32.1 million during the year.
Share Repurchase Program: Concentra repurchased 1.1 million shares totaling $22.4 million during the fourth quarter of 2025. Over the course of 2025, the company executed share repurchases totaling $22.4 million. The Board of Directors has authorized approximately $80 million remaining under the repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company contemplating the impact of weather or elevated respiratory activity on their 2026 guidance?
A:The company does not anticipate much impact from weather or elevated respiratory activity. Weather has not significantly impacted them this year, and respiratory activity, which affects urgent care visits, is not material to their overall operations.
Q:What is the company's thought process on evaluating new opportunities for de novos or M&A in terms of return on invested capital (ROIC)?
A:The company closely monitors the ROIC metric and evaluates projects based on return hurdles and valuation metrics. They have a strong track record of successful M&A and de novo execution, with transactions typically being accretive and having strong ROICs.
Q:Can you provide more details about the New York opportunity and the company's plans if the rules change?
A:The company is advocating for a comprehensive review of the fee schedule, including physical therapy and other codes not addressed in the current rule. They are prepared to move quickly into the New York market, focusing on de novo projects to maximize opportunities and build facilities to their specifications.
Q:What specific items or seasonality should be considered for the 2026 outlook, and what are the plans for de novo investments?
A:The 2026 outlook includes steady visit and rate assumptions, with contributions from the Reliant transaction and 6 planned de novos, potentially more. Seasonality is expected to be similar to prior years, with some pickup in Q1 and Q2 due to prior acquisitions. There are no changes in the number of days compared to 2025.
Q:Is there any cadence consideration related to the expiration of the Select services agreement, and how does it impact margins?
A:The company is hiring the remaining FTEs needed for the separation process, with TSA costs expected to ramp down to zero by mid-2026. There will be incremental costs in the first half of 2026, but this is included in the guidance.
Q:What are the trends in labor retention and wage inflation in the company's clinics?
A:Labor retention is trending favorably, with turnover decreasing and fewer open positions. Wage inflation is in line with historical trends, around 2% to 3%, and the company is not experiencing significant impacts compared to hospitals.
Q:Who is the company taking market share from, and is the growth sustainable? How much of the growth is from de novos?
A:The company is gaining market share through improved go-to-market strategies, deploying new technologies for customer acquisition and retention. De novos contribute less than 1% to growth, as they take time to ramp up.
Q:Are there any expected changes to rates or reimbursement in existing states?
A:California is expected to have a good rate year, and the rest of the country is tracking in line with expectations. There are no significant outliers.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the New York opportunity, particularly regarding the timeline for potential rule changes and the exact impact on their operations. They also used vague language when discussing the sustainability of growth and market share gains, without identifying specific competitors or quantifying the impact of new technologies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Employer Services
GA
Nova Pivot
Pivot acquisition
Select
Services visit
Workers compensation
center segment
claim
comp visit
compensation visit
conjunction
conversion
cost service
deal
employer service
expense
fee schedule
health center
income share
integration
investor
labor market
leverage
majority
novo
novos
rate health
respect
service visit
state
study
visit day
worker compensation
CON Transcript
Escalade, Incorporated (ESCA) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents a mixed picture: while there are positive elements such as improved gross margin, increased EBITDA, and strategic investments, challenges like declining net sales, increased SG&A expenses, and uncertain consumer demand persist. The Q&A session highlights cautious optimism but also reveals management's reluctance to provide specific guidance on tariff refunds. Given these factors, the stock price is likely to remain relatively stable, with potential fluctuations balancing out, resulting in a neutral sentiment.
Concentra Group Holdings Parent, Inc. (CON) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call highlighted strong financial performance, including increased adjusted net income and significant revenue growth from acquisitions. The company raised its revenue and EBITDA guidance, a positive indicator. Despite some vague responses in the Q&A, the overall sentiment was positive with strong market strategy and shareholder return plans. The focus on technological investments and M&A strategy suggests growth potential. The raised guidance and strong financial metrics outweigh any concerns, suggesting a positive stock price reaction over the next two weeks.
Concentra Group Holdings Parent, Inc. (CON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Concentra Group Holdings Parent, Inc. (CON) Q3 2025 Earnings Call Transcript
Positive11-8
The earnings call reveals strong financial performance with significant revenue growth across segments, improved cost efficiency, and optimistic future guidance. Despite decreased free cash flow, the company is bullish about 2026, with no major headwinds anticipated. The Q&A indicates positive sentiment from analysts, highlighting growth in market share and strategic IT investments. While there was some avoidance in addressing the decoupling of BLS data, the overall sentiment remains positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
CON Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
